{"id":"W4399300859","doi":"10.1016/s0140-6736(24)00885-7","title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Foghorn Therapeutics; Servier; National Cancer Institute; Chugai Pharmaceutical; Genentech; European Network for Rare Adult Solid Cancers; Ipsen; PharmaMar; European Society for Medical Oncology; AstraZeneca; Institut National Du Cancer; Pfizer; Symphogen; Incyte; Amgen; Deciphera Pharmaceuticals; Connective Tissue Oncology Society; Karyopharm Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; Iterion Therapeutics; Sanofi; Les Laboratories Pierre Fabre","keywords":"Medicine; Placebo; Clinical endpoint; Population; Surgery; Clinical trial; Internal medicine; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009212429,0.000386254,0.001167499,0.0001017354,0.0002529063,0.0001682149,0.0002455275,0.0001380103,0.0005542175],"category_scores_gemma":[0.0001951457,0.000222294,0.0007029389,0.0001858848,0.00008963916,0.0001257862,0.00005768349,0.0003305601,0.000297104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001366465,"about_ca_system_score_gemma":0.0001758246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001341011,"about_ca_topic_score_gemma":0.00004146823,"domain_scores_codex":[0.9976891,0.0001377821,0.0006050273,0.0004631248,0.0004063967,0.0006985233],"domain_scores_gemma":[0.9978735,0.00118099,0.0001487826,0.0004938571,0.00008698224,0.0002158625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.983048,0.0008143444,0.00000431149,0.0003864476,0.0008997797,0.00009314858,0.0003579787,0.00001689987,0.0005808345,0.0008204531,0.00813176,0.004846085],"study_design_scores_gemma":[0.9580878,0.001845862,0.000005174721,0.0001169292,0.001611499,0.0000211728,0.0001700169,0.003680052,0.001240399,0.0000781857,0.03290534,0.0002375339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9165897,0.002401228,0.001423994,0.009169316,0.007347659,0.02944947,0.0005563405,0.0005793964,0.03248288],"genre_scores_gemma":[0.9821871,0.00014541,0.0004073001,0.0002801385,0.007886462,0.002252375,0.000287762,0.00007385884,0.006479614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06559737,"threshold_uncertainty_score":0.9064885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05800919363486282,"score_gpt":0.3477364504843583,"score_spread":0.2897272568494954,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}